Section 1.4: Molecular Genetics & Pharmacogenomics Foundations

Molecular Genetics & Pharmacogenomics Foundations

The integration of molecular biology principles and pharmacogenomics (PGx) into clinical practice is a key component of the SPLE. Genetic variations among patients significantly influence drug pharmacokinetics and pharmacodynamics, guiding drug selection, dosing, and safety.

---

1. Molecular Biology Fundamentals

The flow of genetic information follows the central dogma: DNA replication, transcription, and translation.

DNA Replication

Occurs during the S phase of the cell cycle in a semi-conservative manner.

• Helicase unwinds the DNA double helix at the replication fork, creating single-stranded templates.
• Primase synthesizes short RNA primers that provide the 3'-OH group required for DNA polymerases.
• DNA Polymerase III is the primary enzyme for synthesizing new strands in the 5'-to-3' direction. It possesses 3'-to-5' exonuclease activity for proofreading.
• DNA Polymerase I removes RNA primers and fills in the gaps.
• DNA Ligase seals nicks in the sugar-phosphate backbone, joining Okazaki fragments on the lagging strand.
• Topoisomerase (Gyrase) relieves supercoiling tension ahead of the replication fork. It is inhibited by fluoroquinolone antibiotics.

Transcription

The process of synthesizing pre-messenger RNA (pre-mRNA) from a DNA template.

• RNA Polymerase II binds to promoter regions (such as the TATA box) to transcribe protein-coding genes.
• Post-Transcriptional Modifications:
  • 5' Capping: Addition of a 7-methylguanosine cap to protect the transcript from degradation.
  • 3' Polyadenylation: Addition of a poly-A tail (~200 adenine nucleotides) to facilitate nuclear export and stability.
  • Splicing: Removal of non-coding introns and joining of coding exons by the spliceosome. Alternative splicing allows a single gene to code for multiple protein isoforms.

Translation

The decoding of mRNA into a polypeptide chain within ribosomes.

• Codons: Three-nucleotide sequences on mRNA that specify particular amino acids. The start codon is AUG (methionine). Stop codons (UAA, UAG, UGA) signal termination.
• Transfer RNA (tRNA): Serves as the adaptor molecule, carrying specific amino acids and pairing its anticodon with the mRNA codon.
• Ribosomes: Consist of large and small subunits (80S in eukaryotes, 70S in prokaryotes). Prokaryotic ribosomes are targets for selective toxicity (e.g., macrolides binding the 50S subunit; tetracyclines binding the 30S subunit).

---

2. Genetic Inheritance and Polymorphisms

• Allele: An alternative form of a gene. A normal, functional allele is referred to as wild-type (typically designated as *1).
• Genotype: The genetic makeup of an organism (homozygous if alleles are identical, heterozygous if they differ).
• Phenotype: The observable physical or biochemical characteristics resulting from the genotype.
• Genetic Polymorphisms: Alterations in the DNA sequence that occur in at least 1% of the population.
  • Single Nucleotide Polymorphism (SNP): A single nucleotide base change (e.g., cytosine replaced by thymine).
  • Insertion/Deletion (Indel): Addition or loss of base pairs.
  • Copy Number Variation (CNV): Micro-duplications, triplications, or whole-gene deletions that lead to altered protein expression levels.

---

3. Pharmacogenomics (PGx) Concepts

Pharmacogenomics is the study of how genetic variation affects individual drug response. In drug metabolism, patients are categorized into phenotypic groups:

1. Poor Metabolizers (PM): Carry two non-functional (loss-of-function) alleles. They have little to no metabolic activity for the enzyme.
2. Intermediate Metabolizers (IM): Carry one functional and one non-functional allele, or two decreased-activity alleles.
3. Normal Metabolizers (NM): Also called Extensive Metabolizers; carry two functional wild-type alleles (normal activity).
4. Ultra-rapid Metabolizers (UM): Carry multiple copies of functional alleles (due to gene duplication), leading to excessively high metabolic activity.

---

4. Key Pharmacogenomic Biomarkers

The Clinical Pharmacogenetics Implementation Consortium (CPIC) and Saudi Food and Drug Authority (SFDA) provide evidence-based guidelines for translating genetic testing results into clinical actions.

CYP2D6

CYP2D6 is a highly polymorphic enzyme that metabolizes ~25% of clinically used drugs.

• Codeine: A prodrug that must be converted to active morphine by CYP2D6 to provide analgesia.
  • Poor Metabolizers: Experience no analgesic effect due to lack of active morphine.
  • Ultra-rapid Metabolizers: Rapidly generate toxic levels of morphine, putting them at high risk for fatal respiratory depression. Codeine is contraindicated in pediatric patients post-tonsillectomy and in breastfeeding mothers who are UMs.
• Tamoxifen: Requires CYP2D6 activation to endoxifen. PMs have lower endoxifen levels and poor breast cancer outcomes.
• Tricyclic Antidepressants (TCAs): PMs need dose reductions due to toxicity risk; UMs need alternative agents due to therapeutic failure.

CYP2C19

• Clopidogrel: An antiplatelet prodrug that requires activation by CYP2C19.
  • Poor Metabolizers (e.g., *2/*2, *2/*3): Have significantly reduced active metabolite levels, leading to poor platelet inhibition and an increased risk of stent thrombosis or myocardial infarction. Guidelines recommend avoiding clopidogrel in CYP2C19 PMs and switching to alternative agents (e.g., prasugrel or ticagrelor).
  • Ultra-rapid Metabolizers (*17/*17): Have increased active metabolite levels and higher bleeding risk.
• Proton Pump Inhibitors (PPIs): PMs have higher drug exposure and superior H. pylori eradication rates, while UMs clear PPIs rapidly and may require higher doses.

CYP2C9 & VKORC1

• Warfarin: CYP2C9 is the primary enzyme metabolizing active S-warfarin. VKORC1 encodes Vitamin K Epoxide Reductase, the pharmacological target of warfarin.
  • CYP2C9 PMs (*2 or *3 alleles): Clear S-warfarin slowly.
  • VKORC1 sensitive variants (e.g., G>A polymorphism): Exhibit increased sensitivity to warfarin.
  • Clinical Action: Patients with these polymorphisms require significantly lower warfarin starting and maintenance doses to prevent severe bleeding complications.

SLCO1B1

• OATP1B1: A hepatic transporter encoded by SLCO1B1 that mediates the uptake of statins (specifically simvastatin) from the blood into the liver.
  • SLCO1B1*5 allele (rs4149056): A loss-of-function variant that reduces transporter activity, leading to decreased hepatic uptake and highly elevated systemic plasma concentrations of simvastatin.
  • Clinical Action: Dramatically increases the risk of concentration-dependent statin-induced myopathy and rhabdomyolysis. Avoid simvastatin 40 mg or 80 mg in carriers of this allele; use lower doses or switch to atorvastatin or rosuvastatin.

TPMT (Thiopurine Methyltransferase)

• Thiopurines (Azathioprine, 6-Mercaptopurine): Used in leukemia and autoimmune conditions. TPMT is the primary metabolizer.
  • Poor Metabolizers (two non-functional alleles, frequency ~0.3%): Suffer from life-threatening myelosuppression (bone marrow suppression) when treated with standard doses.
  • Clinical Action: Screen for TPMT activity or genotype prior to starting therapy; reduce thiopurine doses by 10-fold in PMs.

High-Yield Pharmacogenomic Biomarkers Table